Abstract:Background: Metformin is a first-line drug for treating type 2 diabetes and has gained considerable interest as a potential anticancer agent. Increasing evidence suggests that metformin antagonizes diabetes and tumors through disrupting metabolic homeostasis and altering energy state. However, whether AMP activated protein kinase (AMPK) contributes to such effects of metformin remains controversial. Methods: We performed integrative metabolomics analyses to systematically examine the effects of metformin on metabolic pathways in Prkaa1 wild type (WT) and knock-out (KO) mouse embryonic fibroblast (MEF) cells as well as human cells based on gas chromatography-mass spectrometry and capillary electrophoresis-mass spectrometry (CE-MS). Results: Metformin treatment induced metabolic reprogramming and reduced the energy state of both Prkaa1 WT and KO MEF cells, as evidenced by suppressed tricarboxylic acid (TCA) cycle, elevated lactate production as well as decreased NAD+/NADH ratio. Additionally, metabolic flux analysis also showed that metformin Ampkα-independently increased metabolic flux from glucose to lactate and decreased metabolic flux from acetyl-CoA to TCA cycle as well as from pyruvate to malate. Moreover, metformin Ampkα-dependently upregulated P-Acc but Ampkα-independently inhibited the levels of P-mTor, P-S6, Lc3, Atgl and P-Erk in MEF cells. Similarly, we demonstrated that a commonly used AMPK agonist 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) and fetal bovine serum (FBS) starvation, as a common model for energy stress, both led to Ampkα-independent metabolism alterations in MEF cells. Furthermore, these effects of metformin were also confirmed in human hepatocellular carcinoma (HCC) cells as well as in MCF10A shControl and shPRKAA1 cells. Importantly, we found that metformin could obviously inhibit colony conformation of HCC cells in an Ampkα-independent manner. Conclusions: Our data highlight a comprehensive view of metabolic reprogramming mediated by metformin as well as AICAR. These observations suggest that metformin could affect cellular metabolism largely bypassing Ampkα, and may provide a new insight for its clinical usage.

Metformin Targets Multiple Signaling Pathways in Cancer

Molecular Mechanisms of Metformin for Diabetes and Cancer Treatment

Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing

Non-coding RNAs as potential targets in metformin therapy for cancer

A New Role for an Old Drug: Metformin Targets MicroRNAs in Treating Diabetes and Cancer

Metformin: From Diabetes to Cancer—Unveiling Molecular Mechanisms and Therapeutic Strategies

Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways

Metformin and Cancer Hallmarks: Molecular Mechanisms in Thyroid, Prostate and Head and Neck Cancer Models

Metformin: A Novel but Controversial Drug in Cancer Prevention and Treatment

Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend

Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKα

Metformin is a Novel Suppressor for Transforming Growth Factor (Tgf)-Β1.

Metformin and Cancer: an Existing Drug for Cancer Prevention and Therapy (Review)

Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect

The role of AMPK/mTOR signaling pathway in anticancer activity of metformin.

Advances in Research on the Anticancer Properties and Mechanisms of Metformin in Lung Cancer

Metformin is Associated with Reduced Cell Proliferation in Human Endometrial Cancer by Inbibiting PI3K/AKT/mTOR Signaling.

Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways

Expanding the therapeutic spectrum of metformin: from diabetes to cancer

Metformin as a Potential In Vitro Anticancer Modulator of Adenosine Monophosphate Kinase: A Review

Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis